GLP-1 drugs, addiction and mood
GLP-1 based medicines studied in alcohol and substance use, and their psychiatric effects.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 9, 9, 19, 22, 36.
New guidelines and consensus this year
- AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert ReviewClin Gastroenterol Hepatol2026 Sep 22
- Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)Ann Intern Med2026 Aug
- [Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)]Zhonghua Jie He He Hu Xi Za Zhi2026 Mar 12
All papers from the last 12 months
378 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) eraDrug Alcohol Depend Rep2026 DecPMID 42750843Review
- Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic reviewMetabol Open2026 DecPMID 42750798
- GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic DysfunctionBiol Psychiatry Glob Open Sci2026 NovPMID 42741173Review
- From adiposity to multisystem morbidity: the case for weight loss as disease modificationLancet Diabetes Endocrinol2026 NovPMID 42660161Review
- Safety of semaglutide on depressive symptoms among people with HIV in routine clinical careAIDS2026 Nov 1PMID 42558052
- Saligenin restores insulin responsiveness in lipotoxic myotubes through L-cell-derived GLP-1 via ER stress-autophagy modulationTissue Cell2026 NovPMID 42320358
- GLP-1 Receptor Agonists: Informing Mechanistic Models and Innovative Targets in the Treatment and Prevention of Mental and Substance Use DisordersBiol Psychiatry2026 Oct 15PMID 42749380
- Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder: A Narrative Review of Available Clinical EvidenceBiol Psychiatry2026 Oct 15PMID 42486217Review
- Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to HumansBiol Psychiatry2026 Oct 15PMID 42480803Review
- GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical StudiesBiol Psychiatry2026 Oct 15PMID 42461204Review
More psychiatry trends
All specialties →AI chatbots in mental health
Chatbots and language models used for mental health support.
Key point: PDC30, a self-guided automated intervention with an AI-powered counseling chatbot, improved caregiver depression, burden, and positive gains versus waitlist at 1 month.
Digital mental health apps
Smartphone apps and digital programmes for depression and anxiety.
Key point: Smartphone-delivered lifestyle medicine reduced depressive symptoms more than waitlist control and maintained within-group improvements through 3-month follow-up in probable depression.
ADHD in adults
Diagnosis and treatment of ADHD in adults.
Loneliness and health
Loneliness and social isolation as risk factors.
Gut microbiome and mental health
Links between the gut microbiome and depression or anxiety.
Psilocybin therapy
Psilocybin-assisted therapy for depression and other conditions.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("GLP-1"[tiab] OR semaglutide[tiab] OR liraglutide[tiab]) AND (alcohol[tiab] OR addiction[tiab] OR "substance use"[tiab] OR suicid*[tiab] OR depress*[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.